Stuart M. Gerson Quoted in San Francisco Chronicle on Dendreon ProbeAttorney Highlight July 12, 2007
Stuart M. Gerson, a member of the firm in the Litigation and Health Care & Life Sciences Practices in the Washington, DC office, was quoted in the San Francisco Chronicle about the SEC's informal inquiry into the Seattle-based company Dendreon's experimental cancer vaccine, Provenge.
The article, titled "SEC looks at deals by Dendreon: Biotech company's interactions with FDA under scrutiny," which appeared on July 12, 2007, explores the complex task for biotechnology companies, such as Dendreon, of disclosing important regulatory developments that could affect their stock prices.
Gerson said the SEC is likely trying to determine whether Dendreon officers failed to disclose important information related to the Provenge application that could have affected the company's share price. He added that an SEC informal inquiry does not indicate there has been or will be a finding of wrongdoing.